Dr. Drew Watson is a recognized leader in biostatistics and clinical development with over 25 years of experience. They were instrumental in the development of Oncotype Dx and have founded multiple clinical diagnostics companies, including Nephrosant Inc. Dr. Watson is currently focused on the clinical development and validation of technologies for early detection of various cancers at CellMax Life and serves as Sr. VP of Clinical Studies and Biostatistics. Additionally, they hold an MBA from Golden Gate University and a Ph.D. in Biostatistics from UCLA.
This person is not in the org chart
This person is not in any teams
This person is not in any offices